Theeffect of treprostinil, iloprost and bosentan on T-cell migration Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Bosentan, epoprostenol and iloprost affect migration of human monocytes in vitro Source: Annual Congress 2008 - Regulatory mechanisms of cell activation, renewal and recruitment Year: 2008
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002
Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure Source: Eur Respir J 2003; 22: 342-347 Year: 2003
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002
Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001
Pharmacokinetic differences between inhaled treprostinil and inhaled iloprost in severe pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Transition from nebulised iloprost therapy to subcutaneous treprostinil Source: Eur Respir J 2004; 24: Suppl. 48, 2s Year: 2004
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation Source: Eur Respir J 2002; 19: 518-524 Year: 2002
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Inhaled iloprost plus oral sildenafil as rescue-treatment in life threatening decompensation of primary pulmonary hypertension (PPHT) Source: Eur Respir J 2003; 22: Suppl. 45, 429s Year: 2003
Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005
Inhaled iloprost for the treatment of pulmonary hypertension Source: Eur Respir Rev 2009; 18: 29-34 Year: 2009
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
The acute effect of inhaled salbutamol and ipratropium on microvascular function Source: International Congress 2018 – Basic pharmacology Year: 2018